Generics Global Industry Guide 2015-2024

September 2020 | 273 pages | ID: G59F37C56D9EN
MarketLine

Abstracts

Generics Global Industry Guide 2015-2024

SUMMARY

Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2015-19, and forecast to 2024). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

KEY HIGHLIGHTS

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
• The market value is evaluated at ex-factory prices.
• Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
• Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
• Note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
• All currency conversions were calculated at constant average annual 2019 exchange rates.
• Figures presented in this report are calculated applying the 'middle path' scenario - this is based on the current situation in countries where the epidemic burst first, like China as a model countries and the announcements made by governments, stating that the abnormal situation may last up to six months.
• The assumption has been made that after this time the economy will gradually go back to the levels recorded before the pandemics by the end of the year. It is also assumed that there is no widespread economic crisis as seen back in 2008 due to announced pay-outs across countries.
• At the moment of preparation of this report in July 2020 the economic implications of the lock downs of many economics are still very difficult to predict as there is no indication how long the pandemics could last, the number of sectors forced to stay closed and the scale of the governmental' aid involved.
• The global generics market had total revenues of $339.2bn in 2019, representing a compound annual growth rate (CAGR) of 6.1% between 2015 and 2019.
• Market consumption volume increased with a CAGR of 2.4% between 2015 and 2019, to reach a total of 54.6% in 2019.
• Asia-Pacific accounts for 38.3% of the global market value whilst Europe and the US make up 22.1% and 32.1% respectively.

SCOPE

• Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume

REASONS TO BUY

• What was the size of the global generics market by value in 2019?
• What will be the size of the global generics market in 2024?
• What factors are affecting the strength of competition in the global generics market?
• How has the market performed over the last five years?
• How large is the global generics market in relation to its regional counterparts?

Contents

1 EXECUTIVE SUMMARY

1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Competitive Landscape

2 INTRODUCTION

2.1. What is this report about?
2.2. Who is the target reader?
2.3. How to use this report
2.4. Definitions

3 GLOBAL GENERICS

3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
3.6. Macroeconomic Indicators

4 GENERICS IN ASIA-PACIFIC

4.1. Market Overview
4.2. Market Data
4.3. Market Segmentation
4.4. Market outlook
4.5. Five forces analysis

5 GENERICS IN EUROPE

5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
5.6. Macroeconomic Indicators

6 GENERICS IN FRANCE

6.1. Market Overview
6.2. Market Data
6.3. Market Segmentation
6.4. Market outlook
6.5. Five forces analysis
6.6. Macroeconomic Indicators

7 GENERICS IN GERMANY

7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
7.6. Macroeconomic Indicators

8 GENERICS IN ITALY

8.1. Market Overview
8.2. Market Data
8.3. Market Segmentation
8.4. Market outlook
8.5. Five forces analysis
8.6. Macroeconomic Indicators

9 GENERICS IN JAPAN

9.1. Market Overview
9.2. Market Data
9.3. Market Segmentation
9.4. Market outlook
9.5. Five forces analysis
9.6. Macroeconomic Indicators

10 GENERICS IN AUSTRALIA

10.1. Market Overview
10.2. Market Data
10.3. Market Segmentation
10.4. Market outlook
10.5. Five forces analysis
10.6. Macroeconomic Indicators

11 GENERICS IN CANADA

11.1. Market Overview
11.2. Market Data
11.3. Market Segmentation
11.4. Market outlook
11.5. Five forces analysis
11.6. Macroeconomic Indicators

12 GENERICS IN CHINA

12.1. Market Overview
12.2. Market Data
12.3. Market Segmentation
12.4. Market outlook
12.5. Five forces analysis
12.6. Macroeconomic Indicators

13 GENERICS IN THE NETHERLANDS

13.1. Market Overview
13.2. Market Data
13.3. Market Segmentation
13.4. Market outlook
13.5. Five forces analysis
13.6. Macroeconomic Indicators

14 GENERICS IN SPAIN

14.1. Market Overview
14.2. Market Data
14.3. Market Segmentation
14.4. Market outlook
14.5. Five forces analysis
14.6. Macroeconomic Indicators

15 GENERICS IN THE UNITED KINGDOM

15.1. Market Overview
15.2. Market Data
15.3. Market Segmentation
15.4. Market outlook
15.5. Five forces analysis
15.6. Macroeconomic Indicators

16 GENERICS IN THE UNITED STATES

16.1. Market Overview
16.2. Market Data
16.3. Market Segmentation
16.4. Market outlook
16.5. Five forces analysis
16.6. Macroeconomic Indicators

17 COMPANY PROFILES

17.1. Teva Pharmaceutical Industries Limited
17.2. Pfizer Inc.
17.3. Sun Pharmaceutical Industries Ltd
17.4. Mylan N.V.
17.5. Sanofi SA
17.6. Les Laboratoires Servier
17.7. STADA Arzneimittel AG
17.8. Daiichi Sankyo Co Ltd
17.9. Sawai Pharmaceutical Co Ltd
17.10. Lupin Ltd
17.11. Aspen Pharmacare Holdings Ltd
17.12. Apotex, Inc.
17.13. China Grand Pharmaceutical and Healthcare Holdings Limited
17.14. Esteve Group

18 APPENDIX

18.1. Methodology
18.2. About MarketLine

List Of Tables

LIST OF TABLES

Table 1: Global generics market value: $ billion, 2015–19
Table 2: Global generics market volume: % of total pharma, 2015–19
Table 3: Global generics market geography segmentation: $ billion, 2019
Table 4: Global generics market value forecast: $ billion, 2019–24
Table 5: Global generics market volume forecast: % of total pharma, 2019–24
Table 6: Global size of population (million), 2015–19
Table 7: Global gdp (constant 2005 prices, $ billion), 2015–19
Table 8: Global gdp (current prices, $ billion), 2015–19
Table 9: Global inflation, 2015–19
Table 10: Global consumer price index (absolute), 2015–19
Table 11: Global exchange rate, 2015–19
Table 12: Asia-Pacific generics market value: $ billion, 2015–19
Table 13: Asia–Pacific generics market volume: % of total pharma, 2015–19
Table 14: Asia–Pacific generics market geography segmentation: $ billion, 2019
Table 15: Asia-Pacific generics market value forecast: $ billion, 2019–24
Table 16: Asia–Pacific generics market volume forecast: % of total pharma, 2019–24
Table 17: Europe generics market value: $ billion, 2015–19
Table 18: Europe generics market volume: % of total pharma, 2015–19
Table 19: Europe generics market geography segmentation: $ billion, 2019
Table 20: Europe generics market value forecast: $ billion, 2019–24
Table 21: Europe generics market volume forecast: % of total pharma, 2019–24
Table 22: Europe size of population (million), 2015–19
Table 23: Europe gdp (constant 2005 prices, $ billion), 2015–19
Table 24: Europe gdp (current prices, $ billion), 2015–19
Table 25: Europe inflation, 2015–19
Table 26: Europe consumer price index (absolute), 2015–19
Table 27: Europe exchange rate, 2015–19
Table 28: France generics market value: $ million, 2015–19
Table 29: France generics market volume: % of total pharma, 2015–19
Table 30: France generics market geography segmentation: $ million, 2019
Table 31: France generics market value forecast: $ million, 2019–24
Table 32: France generics market volume forecast: % of total pharma, 2019–24
Table 33: France size of population (million), 2015–19
Table 34: France gdp (constant 2005 prices, $ billion), 2015–19
Table 35: France gdp (current prices, $ billion), 2015–19
Table 36: France inflation, 2015–19
Table 37: France consumer price index (absolute), 2015–19
Table 38: France exchange rate, 2015–19
Table 39: Germany generics market value: $ billion, 2015–19
Table 40: Germany generics market volume: % of total pharma, 2015–19
Table 41: Germany generics market geography segmentation: $ billion, 2019
Table 42: Germany generics market value forecast: $ billion, 2019–24
Table 43: Germany generics market volume forecast: % of total pharma, 2019–24
Table 44: Germany size of population (million), 2015–19
Table 45: Germany gdp (constant 2005 prices, $ billion), 2015–19
Table 46: Germany gdp (current prices, $ billion), 2015–19
Table 47: Germany inflation, 2015–19
Table 48: Germany consumer price index (absolute), 2015–19
Table 49: Germany exchange rate, 2015–19
Table 50: Italy generics market value: $ million, 2015–19

List Of Figures

LIST OF FIGURES

Figure 1: Global generics market value: $ billion, 2015–19
Figure 2: Global generics market volume: % of total pharma, 2015–19
Figure 3: Global generics market geography segmentation: % share, by value, 2019
Figure 4: Global generics market value forecast: $ billion, 2019–24
Figure 5: Global generics market volume forecast: % of total pharma, 2019–24
Figure 6: Forces driving competition in the global generics market, 2019
Figure 7: Drivers of buyer power in the global generics market, 2019
Figure 8: Drivers of supplier power in the global generics market, 2019
Figure 9: Factors influencing the likelihood of new entrants in the global generics market, 2019
Figure 10: Factors influencing the threat of substitutes in the global generics market, 2019
Figure 11: Drivers of degree of rivalry in the global generics market, 2019
Figure 12: Asia-Pacific generics market value: $ billion, 2015–19
Figure 13: Asia–Pacific generics market volume: % of total pharma, 2015–19
Figure 14: Asia–Pacific generics market geography segmentation: % share, by value, 2019
Figure 15: Asia-Pacific generics market value forecast: $ billion, 2019–24
Figure 16: Asia–Pacific generics market volume forecast: % of total pharma, 2019–24
Figure 17: Forces driving competition in the generics market in Asia-Pacific, 2019
Figure 18: Drivers of buyer power in the generics market in Asia-Pacific, 2019
Figure 19: Drivers of supplier power in the generics market in Asia-Pacific, 2019
Figure 20: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2019
Figure 21: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2019
Figure 22: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2019
Figure 23: Europe generics market value: $ billion, 2015–19
Figure 24: Europe generics market volume: % of total pharma, 2015–19
Figure 25: Europe generics market geography segmentation: % share, by value, 2019
Figure 26: Europe generics market value forecast: $ billion, 2019–24
Figure 27: Europe generics market volume forecast: % of total pharma, 2019–24
Figure 28: Forces driving competition in the generics market in Europe, 2019
Figure 29: Drivers of buyer power in the generics market in Europe, 2019
Figure 30: Drivers of supplier power in the generics market in Europe, 2019
Figure 31: Factors influencing the likelihood of new entrants in the generics market in Europe, 2019
Figure 32: Factors influencing the threat of substitutes in the generics market in Europe, 2019
Figure 33: Drivers of degree of rivalry in the generics market in Europe, 2019
Figure 34: France generics market value: $ million, 2015–19
Figure 35: France generics market volume: % of total pharma, 2015–19
Figure 36: France generics market geography segmentation: % share, by value, 2019
Figure 37: France generics market value forecast: $ million, 2019–24
Figure 38: France generics market volume forecast: % of total pharma, 2019–24
Figure 39: Forces driving competition in the generics market in France, 2019
Figure 40: Drivers of buyer power in the generics market in France, 2019
Figure 41: Drivers of supplier power in the generics market in France, 2019
Figure 42: Factors influencing the likelihood of new entrants in the generics market in France, 2019
Figure 43: Factors influencing the threat of substitutes in the generics market in France, 2019
Figure 44: Drivers of degree of rivalry in the generics market in France, 2019
Figure 45: Germany generics market value: $ billion, 2015–19
Figure 46: Germany generics market volume: % of total pharma, 2015–19
Figure 47: Germany generics market geography segmentation: % share, by value, 2019
Figure 48: Germany generics market value forecast: $ billion, 2019–24
Figure 49: Germany generics market volume forecast: % of total pharma, 2019–24
Figure 50: Forces driving competition in the generics market in Germany, 2019